Baker Brothers Investments is an SEC-registered investment adviser based in New York, NY that reports managing 2 hedge funds on Form ADV. It reports $28.1 billion in regulatory assets under management. Its private funds, of all types, hold $28.1 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +13.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +116.6% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $28.1 billionForm ADV Item 5.F
- Gross assets of private funds
- $28.1 billionAll private fund types, Form ADV
- Hedge funds managed
- 22 private funds in total
- Employees
- 60Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 158149
- Latest Form ADV
- 03/27/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +13.5% | +14.8% |
| Q1 2026 | -0.3% | -4.6% |
| Q4 2025 | +18.6% | +2.4% |
| Q3 2025 | +30.7% | +7.8% |
| Q2 2025 | +6.4% | +10.4% |
| Q1 2025 | -1.1% | -4.5% |
| Q4 2024 | -3.8% | +2.1% |
| Q3 2024 | +22.0% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 79 share positions ($20,988,985,093) reported by Baker Bros. Advisors LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Incyte Corp17.79%
- Beone Medicines LTD15.40%
- Revolution Medicines Inc10.40%
- Kodiak Sciences Inc9.87%
- Madrigal Pharmaceuticals Inc5.15%
- Insmed Inc4.78%
- Kymera Therapeutics Inc4.61%
- Acadia Pharmaceuticals Inc4.12%
- Grail Inc2.69%
- Summit Therapeutics Inc2.64%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Incyte Corp | $3,733,047,820 | 17.79% | 30,762,652 | Unchanged |
| Beone Medicines LTD | $3,232,104,670 | 15.40% | 8,832,335 | +0.35% |
| Revolution Medicines Inc | $2,183,415,893 | 10.40% | 10,637,318 | -7.04% |
| Kodiak Sciences Inc | $2,072,417,207 | 9.87% | 21,860,941 | +9.75% |
| Madrigal Pharmaceuticals Inc | $1,080,052,299 | 5.15% | 2,143,131 | Unchanged |
| Insmed Inc | $1,003,988,110 | 4.78% | 8,796,111 | Unchanged |
| Kymera Therapeutics Inc | $967,793,083 | 4.61% | 8,657,242 | Unchanged |
| Acadia Pharmaceuticals Inc | $864,695,016 | 4.12% | 42,912,904 | Unchanged |
| Grail Inc | $564,489,394 | 2.69% | 4,028,614 | Unchanged |
| Summit Therapeutics Inc | $554,417,145 | 2.64% | 32,786,348 | Unchanged |
| Rhythm Pharmaceuticals Inc | $533,630,849 | 2.54% | 5,604,483 | Unchanged |
| Praxis Precision Medicines I | $510,583,854 | 2.43% | 1,753,198 | Unchanged |
| Abcellera Biologics Inc | $481,647,108 | 2.29% | 33,012,139 | Unchanged |
| Alkermes PLC | $405,697,059 | 1.93% | 10,012,267 | Unchanged |
| Celcuity Inc | $382,951,780 | 1.82% | 4,815,792 | -39.16% |
| Kiniksa Pharmaceuticals Intl | $211,492,714 | 1.01% | 2,834,643 | Unchanged |
| Ideaya Biosciences Inc | $192,485,353 | 0.92% | 5,010,030 | Unchanged |
| Edgewise Therapeutics Inc | $150,289,791 | 0.72% | 3,701,719 | Unchanged |
| Replimune Group Inc | $146,240,249 | 0.70% | 11,045,336 | Unchanged |
| Roivant Sciences LTD | $133,859,073 | 0.64% | 3,660,352 | -22.40% |
| Arrowhead Pharmaceuticals In | $111,857,519 | 0.53% | 1,709,053 | -14.24% |
| Nurix Therapeutics Inc | $110,454,363 | 0.53% | 4,658,556 | Unchanged |
| Immunovant Inc | $93,583,335 | 0.45% | 2,770,377 | -49.03% |
| Celldex Therapeutics Inc New | $83,131,131 | 0.40% | 2,564,984 | +116.89% |
| Denali Therapeutics Inc | $77,188,725 | 0.37% | 3,734,336 | Unchanged |
| Dianthus Therapeutics Inc | $75,033,040 | 0.36% | 852,164 | Unchanged |
| Rapport Therapeutics Inc | $51,982,224 | 0.25% | 1,547,090 | Unchanged |
| Monte Rosa Therapeutics Inc | $51,844,630 | 0.25% | 4,345,736 | Unchanged |
| Relay Therapeutics Inc | $51,023,433 | 0.24% | 2,826,783 | Unchanged |
| Ionis Pharmaceuticals Inc | $45,715,528 | 0.22% | 1,023,864 | -50.00% |
| Structure Therapeutics Inc | $44,795,182 | 0.21% | 1,432,529 | Unchanged |
| Enliven Therapeutics Inc | $41,493,955 | 0.20% | 905,191 | Unchanged |
| Bicycle Therapeutics PLC | $40,058,114 | 0.19% | 10,885,357 | Unchanged |
| Prelude Therapeutics Inc | $39,584,152 | 0.19% | 10,123,824 | Unchanged |
| Mirum Pharmaceuticals Inc | $38,121,943 | 0.18% | 445,975 | Unchanged |
| Design Therapeutics Inc | $37,560,970 | 0.18% | 2,988,144 | +11.56% |
| Immatics N.V | $37,373,668 | 0.18% | 4,256,682 | -55.23% |
| Stoke Therapeutics Inc | $34,163,974 | 0.16% | 1,313,999 | -60.62% |
| Entrada Therapeutics Inc | $32,211,836 | 0.15% | 5,072,730 | Unchanged |
| Neurogene Inc | $27,588,844 | 0.13% | 991,691 | Unchanged |
| Xencor Inc | $27,497,545 | 0.13% | 1,102,106 | Unchanged |
| Faeth Therapeutics Inc | $23,893,860 | 0.11% | 803,425 | -37.55% |
| Absci Corporation | $22,991,828 | 0.11% | 2,134,803 | Unchanged |
| Disc Medicine Inc | $22,888,547 | 0.11% | 349,657 | Unchanged |
| Arcus Biosciences Inc | $21,821,597 | 0.10% | 844,816 | Unchanged |
| Generate Biomedicines Inc | $21,382,502 | 0.10% | 1,423,602 | Unchanged |
| Taysha Gene Therapies Inc | $19,503,162 | 0.09% | 4,004,756 | Unchanged |
| Aktis Oncology Inc | $19,398,954 | 0.09% | 996,351 | Unchanged |
| Jade Biosciences Inc | $17,287,485 | 0.08% | 1,230,426 | Unchanged |
| DBV Technologies S A | $17,186,358 | 0.08% | 1,461,425 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 5 new positions, 9 sold out, 7 increased, 11 reduced and 56 unchanged.
Number of positions (a count, not dollars)
- New positions5
- Increased7
- Unchanged56
- Reduced11
- Sold out9
New positions
| Stock | Value | Shares |
|---|---|---|
| First Tracks Biotherapeutics | $16,760,710 | 472,932 |
| Scribe Therapeutics Inc. | $12,675,358 | 688,691 |
| Freenome, Inc. | $12,519,801 | 794,908 |
| Q32 Bio Inc | $4,531,505 | 547,945 |
| Skye Bioscience, Inc. | $317,017 | 196,905 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Crinetics Pharmaceuticals In | $87,991,820 | 2,351,465 |
| Alumis Inc | $56,631,750 | 2,012,500 |
| Viridian Therapeutics Inc | $43,776,169 | 2,383,025 |
| Sionna Therapeutics Inc | $17,596,000 | 400,000 |
| Verastem Inc | $9,547,471 | 2,499,338 |
| Sagimet Biosciences Inc | $7,366,659 | 952,996 |
| Wave Life Sciences LTD | $4,779,527 | 822,638 |
| Skye Bioscience Inc | $1,092,116 | 1,575,243 |
| Surrozen Inc | $13,750 | 833,333 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Kodiak Sciences Inc | +1,941,755 | +9.75% | $2,072,417,207 | 21,860,941 |
| Celldex Therapeutics Inc New | +1,382,373 | +116.89% | $83,131,131 | 2,564,984 |
| Beone Medicines LTD | +30,768 | +0.35% | $3,232,104,670 | 8,832,335 |
| Design Therapeutics Inc | +309,714 | +11.56% | $37,560,970 | 2,988,144 |
| Evommune Inc | +387,404 | +45.72% | $10,199,398 | 1,234,794 |
| Protara Therapeutics Inc | +872,181 | +89.77% | $5,623,575 | 1,843,795 |
| Maplight Therapeutics Inc | +72,648 | +6.64% | $11,889,315 | 1,166,763 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Celcuity Inc | -3,100,000 | -39.16% | $382,951,780 | 4,815,792 |
| Revolution Medicines Inc | -806,039 | -7.04% | $2,183,415,893 | 10,637,318 |
| Immunovant Inc | -2,664,843 | -49.03% | $93,583,335 | 2,770,377 |
| Stoke Therapeutics Inc | -2,022,698 | -60.62% | $34,163,974 | 1,313,999 |
| Immatics N.V | -5,251,883 | -55.23% | $37,373,668 | 4,256,682 |
| Ionis Pharmaceuticals Inc | -1,023,863 | -50.00% | $45,715,528 | 1,023,864 |
| Roivant Sciences LTD | -1,056,479 | -22.40% | $133,859,073 | 3,660,352 |
| Arrowhead Pharmaceuticals In | -283,730 | -14.24% | $111,857,519 | 1,709,053 |
| Faeth Therapeutics Inc | -482,986 | -37.55% | $23,893,860 | 803,425 |
| Cerus Corp | -4,062,276 | -63.52% | $5,552,909 | 2,333,155 |
| Intellia Therapeutics Inc | -101,179 | -10.88% | $9,998,379 | 829,053 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Neurogene Inc. | 13G amendment | 4.99% | 1,034,522 | Nov 16, 2026 | SEC.gov ↗ |
| Stoke Therapeutics, Inc. | 13G amendment | 4.7% | 3,165,864 | Nov 16, 2026 | SEC.gov ↗ |
| Revolution Medicines, Inc. | 13G amendment | 4.92% | 10,637,318 | Nov 16, 2026 | SEC.gov ↗ |
| Immatics N.V. | 13G amendment | 2.8% | 4,256,682 | Nov 16, 2026 | SEC.gov ↗ |
| Madrigal Pharmaceuticals, Inc. | 13D amendment | 9.99% | 2,330,144 | Nov 6, 2026 | SEC.gov ↗ |
| Kodiak Sciences Inc. | 13D amendment | 35% | 22,049,297 | Sep 30, 2026 | SEC.gov ↗ |
| BeOne Medicines Ltd. | 13D amendment | 7.8% | 115,457,154 | Sep 16, 2026 | SEC.gov ↗ |
| IDEAYA Biosciences, Inc. | 13G | 5.2% | 5,010,030 | Aug 14, 2026 | SEC.gov ↗ |
| Edgewise Therapeutics, Inc. | 13G amendment | 3.4% | 3,701,719 | Aug 14, 2026 | SEC.gov ↗ |
| Cerus Corporation | 13G amendment | 3.2% | 6,395,431 | Aug 14, 2026 | SEC.gov ↗ |
| Replimune Group, Inc. | 13D amendment | 11.8% | 11,075,336 | Aug 11, 2026 | SEC.gov ↗ |
| Celcuity Inc. | 13G | 9.99% | 4,877,963 | Jul 16, 2026 | SEC.gov ↗ |
| Kiniksa Pharmaceuticals International, plc | 13D amendment | 6.9% | 3,231,181 | May 26, 2026 | SEC.gov ↗ |
| Monte Rosa Therapeutics, Inc. | 13G amendment | 9.99% | 8,876,346 | May 15, 2026 | SEC.gov ↗ |
| GRAIL, Inc. | 13G amendment | 9.8% | 4,028,614 | May 15, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Dec 11, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 25 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Private investment funds filing Form D (1)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures